Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

John Waples (NPI 1790765337)

Field	Value
Entity Type	Individual
Organization	John Waples
Address	3601 Cci Dr Nw
City	Huntsville
State	AL
ZIP	35805
Taxonomy	Medical Oncology Physician
NPI Enumerated	January 19, 2006

Payer Source	Total Paid
Medicare	$9.6M
Medicaid	$0

Key Findings

This provider’s Medicare revenue profile is dominated by high-cost oncology drug administrations: J9271, J9299, and J0897 are the top chemotherapy/biologic drug codes, and the presence of infusion administration codes such as 96413 and G0498 supports an infusion-centric oncology practice model rather than a primarily office-based consultative role. The code mix (checkpoint inhibitors, monoclonal antibodies, bone-targeting agents and supportive infusions) is consistent with a medical oncology infusion clinic delivering immuno-oncology and biologic therapies.

Revenue concentration is high: Total Medicare revenue is $9.6M and the precomputed top-3 contribution is explicit — Top 3 Medicare codes by revenue account for 51.3% of this provider's total Medicare revenue — indicating a small set of drug therapies drives the majority of Medicare receipts. This concentration suggests the provider’s financial performance is tightly linked to utilization of a few expensive agents.

Payer mix is effectively single-payer Medicare: Total Medicaid revenue is none (no Medicaid billing on file), so all reported public-payer activity in the dataset is Medicare. For payer-strategy or network analyses, this provider should be treated as Medicare-dominant with no Medicaid footprint to measure against in-state peers.

The provider is a national high-volume outlier on several leading oncology drugs, signaling dominant competitive standing for those agents: J9271 ranks #9 of 1841 providers nationally (100th percentile; extreme outlier), J9299 ranks #5 of 505 providers nationally (99th percentile; extreme outlier), and J0897 ranks #25 of 10057 providers nationally (100th percentile; extreme outlier). These rank positions place the provider among the top national billers for key immunotherapy and biologic agents rather than a typical community-volume practice for those drugs.

Procedural and visit volumes also show marked concentration: 99214 (office established visit) ranks #1360 of 479517 providers nationally (100th percentile; extreme outlier) and chemotherapy administration 96413 ranks #8 of 7514 providers nationally (100th percentile; extreme outlier), while G0498 ranks #9 of 896 providers nationally (99th percentile; extreme outlier). Together these outlier positions indicate the provider combines high-volume drug infusion activity with substantial office/clinic follow-up and infusion-initiation services.

The provider exhibits notable adoption of biosimilars and specialty supportive agents: Q5123 (rituximab-arrx) ranks #1 of 40 providers nationally (100th percentile; notably above typical national volume) and Q5127 (pegfilgrastim-fpgk) ranks #2 of 30 providers nationally (97th percentile; notably above typical national volume), while Q5126 and other biosimilars are also present in the top-25. This pattern suggests an operational emphasis on delivering both originator and biosimilar biologic therapies, which may reflect internal protocols for growth-factor support and monoclonal antibody treatment.

Tenure and scale point to an established specialty practice: the NPI was enumerated on 2006-01-19 (~20 years ago), and the provider has accumulated $9.6M in Medicare revenue over the lifetime measures reported. The combination of long enumeration history with high, concentrated drug billing is consistent with a mature oncology infusion operation rather than a newly established clinic.

Because more than half of Medicare revenue is concentrated in the top three drug codes (Top 3 Medicare codes by revenue account for 51.3% of total Medicare revenue) and multiple drugs rank as national extreme outliers, the provider’s revenue base may be sensitive to shifts in utilization patterns, reimbursement policies, or formulary decisions affecting those specific agents. Analysts evaluating contract negotiations or network management should note the provider’s reliance on a narrow set of high-cost oncology therapies when modeling financial impact of payer policy changes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

122 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	56,800	$40	$2.4M
J9299	Injection, nivolumab, 1 mg	55,600	$20	$1.3M
J0897	Injection, denosumab, 1 mg	46,680	$20	$840.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	17,280	$40	$656.6K
J9173	Injection, durvalumab, 10 mg	8,730	$60	$541.5K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	13,990	$30	$461.7K
J1930	Injection, lanreotide, 1 mg	9,840	$40	$433K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	7,390	$40	$273.4K
J1437	Injection, ferric derisomaltose, 10 mg	15,000	$20	$255K
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	900	$270	$243.9K

Showing 1–10 of 122

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 122 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

John Waples — 17 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

122 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	30	19,900	$40	$827.2K
J9299	1	10	19,060	$20	$535.1K
J9173	1	10	8,340	$60	$517.6K
J9144	1	10	11,880	$40	$443.8K
J1930	1	10	9,840	$40	$431.7K
J1568	6	30	5,180	$30	$316.2K
J1561	1	10	7,390	$40	$274.6K
Q5126	1	10	3,830	$60	$217K
J9264	1	10	17,400	$10	$167.5K
Q5127	2	20	590	$270	$165.7K

Showing 1–10 of 122

Related Providers

Other providers that share a Tax Identification Number (TIN) with John Waples, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Robert Conry	AL	Hematology & Oncology Physician	$2.1M	$0
Lakshmikanth Katragadda	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M
Surrinder Dang	AL	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as John Waples, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Huntsville Emergency Medical Services, Inc.	AL	Land Ambulance	$5.6M	$6M
Madison Core Laboratories, LLC	AL	Clinical Medical Laboratory	$1.5M	$4M
Hc Healthcare, LLC	AL	Community Based Hospice Care Agency	$0	$4.8M
The Village Medical Clinic	AL	Specialist	$0	$2M
Ehab El-bahesh	AL	Hematology & Oncology Physician	$1.7M	$0
Pathology Associates, P.C.	AL	Anatomic Pathology & Clinical Pathology Physician	$0	$1.7M
Rehabilitation & Neurological Services LLC	AL	Specialist	$0	$1.3M
Philip Mcgee	AL	Hematology & Oncology Physician	$1.2M	$0
John Nicholson	AL	Hematology & Oncology Physician	$1.2M	$0
Elizabeth Falkenberg	AL	Radiation Oncology Physician	$1.1M	$0

John Waples — Billing Profile & Reimbursement Data

Sign up for John Waples — Billing Profile & Reimbursement Data policy alerts

John Waples — Billing Profile & Reimbursement Data

Sign up for John Waples — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References